Preferential Binding of Staphylococcus aureus to Skin Sites of Th2-Mediated Inflammation in a Murine Model  by Cho, Sang-Hyun et al.
Preferential Binding of Staphylococcus aureus to Skin Sites of
Th2-Mediated In¯ammation in a Murine Model
Sang-Hyun Cho,*1 Ian Strickland,*1 Adrian Tomkinson,*² Amy P. Fehringer,* Erwin W. Gelfand,*²³
and Donald Y.M. Leung*³
Divisions of *Allergy-Immunology and ²Cell Biology, Department of Pediatrics, National Jewish Medical and Research Center, Denver, Colorado,
U.S.A.; ³Department of Pediatrics, University of Colorado Health Sciences Center, Denver, Colorado, U.S.A.
Staphylococcus aureus is found on over 90% of atopic
dermatitis skin lesions and is thought to contribute to
skin in¯ammation via the production of potent exo-
toxins. In contrast, less than 5% of normal subjects
harbor S. aureus. This suggests that an atopic immune
response itself may play a role in preferential binding
of S. aureus to the skin. To examine this issue more
directly, we analyzed the S. aureus binding character-
istics of skin in mice undergoing different T helper
type 1 cell versus T helper type 2 cell in¯ammatory
responses using a novel in vitro bacterial binding
assay. BALB/C female mice were ®rst sensitized to
ovalbumin with alum or ovalbumin with complete
Freund's adjuvant to induce T helper type 2 or T
helper type 1 responses, respectively. Mice were then
challenged intradermally with either saline (control)
or ovalbumin. Forty-eight hours later, skin specimens
were obtained from the challenge sites, and the
number of S. aureus binding to each skin section was
quantitated. Bacterial binding was found to be sig-
ni®cantly greater at skin sites of BALB/C mice that
had been ovalbumin/alum sensitized compared with
ovalbumin/complete Freund's adjuvant sensitized
(p < 0.01). When compared to the ovalbumin sensit-
ized/challenged skin of wild type BALB/C mice or
interferon-g gene knockout mice, interleukin-4, but
not interferon-g, gene knockout mice had signi®c-
antly less S. aureus binding at their ovalbumin sensit-
ized/challenged skin sites. Mutant S. aureus strains
that lacked either ®bronectin- or ®brinogen-binding
protein expression showed signi®cantly reduced S.
aureus binding compared with the parent wild type
strain (p < 0.005). Moreover, preincubation of the
wild type bacteria with ®bronectin or ®brinogen, but
not collagen, resulted in signi®cantly less skin binding
of S. aureus (p < 0.01). Incubation of skin with inter-
leukin-4, and less so with interferon-g, led to more
binding of wild type S. aureus but not of an S. aureus
mutant de®cient in ®bronectin binding protein
expression. After interleukin-4 incubation, but not
interferon-g, epidermal immunoreactivity for ®bro-
nectin was observed in murine skin explants. These
results show that a T helper type 2 in¯ammatory
environment can promote skin binding by S. aureus
and that this binding is mediated by ®bronectin and
®brinogen. Key words: atopic dermatitis/collagen/®bronec-
tin/®brinogen. J Invest Dermatol 116:658±663, 2001
A
topic dermatitis (AD) is a chronic in¯ammatory skin
disease affecting over 10% of children, and is a major
cause of occupation-related disability caused by skin
disease (Leung, 2000). More than 90% of AD patients
are colonized with Staphylococcus aureus on their skin
lesions and on unaffected skin as well (Leyden et al, 1974). In
contrast, only 5% of normal subjects carry S. aureus on their skin
and it is localized mainly in the nose and intertriginous areas.
Numerous reports suggest that this bacterium has an important role
in the exacerbation and chronicity of AD through the release of
toxins (Leung et al, 1993a; Bunikowski et al, 1999; Nomura et al,
1999). Some of these toxins are superantigenic in nature and deliver
strong activating signals to macrophages and T cells, thus
augmenting skin in¯ammatory responses (Kotzin et al, 1993). The
excellent response to antistaphylococcal antibiotics in the treatment
of poorly controlled AD strongly suggests that this bacterium can be
involved in the perpetuation of chronic AD (Lever et al, 1988).
Due to increasing concerns over the emergence of antibiotic-
resistant S. aureus, it is imperative to understand the mechanisms by
which S. aureus binds to atopic skin and identify potential
therapeutic targets for reduction of S. aureus colonization.
The mechanism by which S. aureus is able to successfully
colonize the skin of AD patients is largely unknown. There is
considerable evidence, however, that acute skin in¯ammation in
AD is primarily mediated by T helper type 2 (Th2) cells (Hamid
et al, 1994, 1996). Treatment with topical steroids has been shown
to reduce skin colonization with S. aureus suggesting that it is the
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in¯ammatory process that drives attachment of S. aureus to atopic
skin (Nilsson et al, 1992). In psoriasis, which is a chronic
in¯ammatory skin disease mediated by Th1 cells, S. aureus
colonization occurs in only approximately 50% of patients and
generally involves several log-fold fewer numbers of S. aureus per
square centimeter of skin than in AD (Leung et al, 1993a,b). Thus,
it would be of interest to know whether S. aureus attachment to
Th1- versus Th2-mediated skin lesions differs.
Recent studies have demonstrated that S. aureus strains express a
distinct array of surface proteins, termed microbial surface com-
ponents recognizing adhesive matrix molecules (MSCRAMMs),
that recognize human extracellular matrix (ECM) proteins. This
family of microbial cell surface proteins has been shown to
speci®cally bind ECM proteins such as ®bronectin and collagen
(Foster and HoÈoÈk, 1998), implicating these proteins as potential
ligands for S. aureus binding to AD skin. In addition, all S. aureus
strains bind ®brinogen. The potential role of these molecules in S.
aureus binding to in¯amed skin has not previously been explored.
To address these questions, two previously established murine
models of skin in¯ammation were utilized in this study: ®rst, a
model of Th1-induced, interferon-g (IFN-g) skin in¯ammation
where BALB/C mice were sensitized to ovalbumin (OVA) in the
presence of complete Freund's adjuvant (CFA) and then OVA
challenged; second, a model of Th2-induced interleukin-4 (IL-4)
mediated skin in¯ammation in which an OVA/alum sensitization
was followed by an OVA challenge regimen (Beck and
Spiegelberg, 1989; Ke et al, 1995; Sawada et al, 1997; Spergel
et al, 1998; 1999). We also took advantage of the availability of
mice with targeted deletions of the IL-4 gene and IFN-g gene and
S. aureus isogenic mutant strains that were selectively de®cient in
speci®c MSCRAMM genes to explore the role of cytokines and
MSCRAMMs in the binding of S. aureus to sites of allergic skin
in¯ammation.
MATERIALS AND METHODS
Bacterial strains Two sources of S. aureus strains were utilized in this
study: S. aureus cultured from the lesions of AD patients and isogenic
mutants of S. aureus that had been generated by allele replacement or
transposon mutagenesis to eliminate the expression of speci®c
MSCRAMMs, i.e., ®bronectin binding protein (FnbpA and FnbpB),
®brinogen binding protein (ClfA and ClfB), or collagen binding protein
(Cna), together with their corresponding wild type (WT) parent strains.
The isogenic mutant strains were: (i) strain DU5883, which is the
FnbpA- and FnbpB-negative mutant (8325±4 fnbA::TcR fnbB::EmR) of
S. aureus strain 8325±4 kindly provided by Professor Timothy J. Foster,
Trinity College, Dublin, Ireland (Greene et al, 1995); (ii) strain DU5944,
which is the ClfA- and ClfB-negative mutant (Newman clfA2::Tn917
clfB::TcR) of the Newman S. aureus strain, also provided by Dr. Foster
(Ni Eidhin et al, 1998); (iii) strain PH100, which is a collagen adhesin-
negative mutant (Phillips cna::GmR) made in S. aureus strain Phillips,
generously provided by Dr. Magnus HoÈoÈk (Texas A & M University,
Houston, TX) (Patti et al, 1994). For each of these mutant strains of
S. aureus, we had the corresponding WT S. aureus parent strain 8325±4
and Newman (from Dr. Foster) and Phillips (from Dr. HoÈoÈk) for
comparison of baseline binding to skin sections.
Sensitization of mice and preparation of skin sections BALB/C
female mice (Jackson Laboratories, Bar Harbor, ME), IL-4 knockout
(IL-4 KO) female mice with a BALB/C background, and IFN-g
knockout (IFN-g KO) female mice with a C57BL/6 background were
sensitized by intraperitoneal injection of 20 mg OVA (grade V, Sigma)
emulsi®ed in 2.25 mg aluminum hydroxide (AlumImuject: Pierce,
Rockford, IL) (to produce a Th2 response) or CFA (50% vol/vol, ®nal
concentration; Sigma) (to produce a Th1 response) in a total volume of
100 ml on days 1 and 14 as previously described (Sawada et al, 1997). On
day 21, the abdomens of the sensitized mice were shaved, then
challenged intradermally with 100 ml injections of OVA solution [500 mg
per ml in phosphate-buffered saline (PBS)] or vehicle alone (PBS) at
single sites and left for 48 h to allow the development of a Th2
in¯ammatory reaction at the OVA site. After antigen skin challenges, the
mice were sacri®ced by cervical dislocation and skin biopsies were taken
from both the saline control and challenge sites, snap frozen in OCT
(Triangle Biomedical Sciences, Durham, NC), and then stored at ±70°C
until use. Frozen sections 10 mm in cross-section were then prepared and
used for bacterial binding experiments as described below. The level of
in¯ammation was found to be comparable between groups as assessed by
hematoxylin and eosin histologic staining.
In a further attempt to con®rm the effect of Th1 versus Th2 immune
responses on bacterial adherence to the skin, mouse skin explants were
incubated in mouse recombinant IL-4 or recombinant IFN-g (R&D
Systems, Minneapolis, MN). In these experiments, fresh skin specimens
from BALB/C mice were cut into 4 mm pieces. Each piece of skin
tissue was incubated in RPMI 1640 culture medium with recombinant
IL-4 (1000 U per ml) or IFN-g (1000 U per ml), or medium alone at
37°C for 72 h. After these incubations, skin tissues were washed three
times with PBS and snap frozen in OCT, and then cryostat sections
10 mm in cross-section were prepared for assessment of S. aureus binding.
Bacteria binding assay Staphylococcus aureus were streaked for isolation
on blood agar plates (Remel, Lenexa, KS) and incubated overnight at
37°C. One colony from each plate was picked, inoculated into 1%
human serum albumin (HSA)/tryptic soy broth (Becton Dickinson,
Sparks, MD), and incubated for 4 h at 37°C with gentle shaking to
achieve early logarithmic growth phase. Bacteria were harvested by
10 min of centrifugation at 3000 rpm and washed twice with sterile
PBS. Bacteria were re-suspended in sterile PBS to a concentration of
about 107 colony-forming units per ml. Before every experiment,
bacteria were incubated with 1% HSA for 1 h at room temperature to
block nonspeci®c binding sites. Bacteria were then pelleted by
centrifugation, washed twice with sterile PBS, and then re-suspended at
a ®nal concentration of 1 3 107 per ml in sterile PBS before use.
One hundred microliters of each bacterial suspension (106 bacteria)
were added to each skin specimen previously washed with PBS to
remove any residual serum antibody. The skin sections were then
incubated with the bacteria for 60 min at room temperature on a
rotating table in a humidi®ed atmosphere to allow bacterial adherence to
the skin sections. After this incubation period, sections were washed in
PBS twice to remove unbound bacteria from the skin sections, treated
with 1% (wt/vol) paraformaldehyde (Sigma) in PBS for 10 min at room
temperature, washed twice in PBS, and then air-dried. Adherent bacteria
were then visualized by a standard Gram staining procedure. In brief,
slides were ®xed by passing through a ¯ame, immersed in crystal violet
for 1 min, and then gently washed in water. Slides were immersed in
Gram iodine for 1 min, washed in water, then decolorized with acetone-
alcohol and washed in water. Slides were blotted dry with ®lter paper
and mounted in a permanent mounting medium (VectaMount, Vector,
Burlington, CA). The number of bacteria bound to each skin section
was quantitated microscopically by a blinded assessor and then expressed
as number of bacteria bound per high power ®eld (3 1000); a minimum
of three ®elds were counted. Bacterial adherence was also quantitated in
relation to the epidermal strata they were bound to, the stratum corneum
or subcorneal epithelium.
To further demonstrate the role of ECM proteins in bacterial
adherence to epidermis in selected experiments, S. aureus were incubated
with 10 mg per ml of ®bronectin, ®brinogen, or type I collagen (Sigma),
or 1% HSA as a control for 2 h at room temperature. Bacteria were
harvested by 10 min of centrifugation, washed twice with PBS, and re-
suspended at a concentration of 10 3 106 per ml in sterile PBS. One
hundred microliters of each bacterial strain was pipetted sequentially onto
individual skin sections derived from each subject group. The S. aureus
binding and staining procedure was carried out as described above.
Fibronectin staining of murine skin Normal BALB/C mouse skin
was excised, washed in PBS to remove any residual serum, and then
incubated for 48 h at 37°C, in either medium alone (RPMI, 10% fetal
bovine serum) or medium with 1000 U per ml of either mouse IL-4 or
IFN-g (R&D Systems). After 48 h the explants were washed twice in
PBS and snap frozen, and frozen sections 5 mm in cross-section were
prepared for immunostaining. Sections were blocked for 10 min at room
temperature with a commercial blocking solution (Superblock, Scytek,
Logan, UT). The blocking solution was then aspirated and sections were
incubated overnight at 4°C with a 1:50 dilution of anti®bronectin rabbit
polyclonal antibody (Sigma). After this incubation period, sections were
washed in 1 3 PBS, and incubated at room temperature for 1 h with an
antirabbit ¯uorescein isothiocyanate conjugated antibody (Dako,
Carpinteria, CA) at a ®nal dilution of 1:50 in PBS. Sections were again
washed in 1 3 PBS and then mounted using a 50% (vol/vol) solution of
glycerol (Sigma) in 1 3 PBS and assessed by ¯uorescence microscopy.
Intensity of staining was quanti®ed by image analysis (IP Laboratory
Spectrum, Signal Analytics, Vienna, VA) and expressed as mean
¯uorescence intensity (MFI). To ensure speci®c quanti®cation of staining
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within the epithelium, multiple small gates were created using the image
analysis software. This ensured that readings were taken solely within the
epithelial layer.
Statistical analysis The number of bacteria bound/hpf was expressed
as the mean 6 SEM. Differences observed between groups were
determined by using an unpaired, two-tailed Student t test. Probability
(p) values of less than 0.05 were considered statistically signi®cant.
RESULTS
Adherence of S. aureus to Th1- and Th2-mediated sites of
skin in¯ammation Staphylococcus aureus isolated from AD skin
lesions of 37 different patients were analyzed by polymerase chain
reaction for MSCRAMM gene expression. The majority of S.
aureus expressed genes for FnBP, Clf, and Cna (data not shown).
These S. aureus all had similar binding characteristics to mouse
experiments. We therefore selected one representative AD S. aureus
strain to examine differential binding to mouse epidermis that was
associated with lack of in¯ammation (saline control) versus Th1-
mediated in¯ammation (OVA/CFA-sensitized) versus Th2-
mediated in¯ammation (OVA/alum-sensitized). Similar data were
observed with other strains of S. aureus.
As shown in Figs 1 and 2, bacterial binding was found to be
signi®cantly greater to the stratum corneum of BALB/C mice that
had been OVA/alum sensitized (Th2 response) than to OVA/
CFA-sensitized mice. OVA/CFA-sensitized mice (Th1 response)
showed no increase in bacterial binding compared with saline-
challenged skin. The S. aureus binding to challenged sites from the
OVA/alum-sensitized mice, however, was signi®cantly higher than
that of OVA/CFA-sensitized mice (p < 0.01). Furthermore,
binding to subcorneal epithelium was signi®cantly higher in the
OVA/alum-sensitized mice than in OVA/CFA-sensitized mice (p
< 0.01).
Baseline S. aureus binding to the skin of OVA-sensitized/
challenged mice was not signi®cantly different between BALB/C
mice, IL-4 KO mice, and IFN-g KO mice (Fig 3). Compared with
the OVA-sensitized/challenged skin of BALB/C mice, however,
the IL-4 KO mice showed signi®cantly less binding than WT
animals (p < 0.0001). The IFN-g KO mice also showed less S.
aureus binding (p < 0.0005), but the binding was signi®cantly
higher than found in the IL-4 KO mice (p < 0.0001).
The effect of blocking MSCRAMMs on S. aureus
adherence To determine which MSCRAMMs are involved in
the binding of S. aureus to Th2-mediated in¯amed skin, S. aureus
from AD were incubated with ®bronectin, collagen, or ®brinogen
in an attempt to block MSCRAMM receptors and thus inhibit
bacterial binding (Fig 4). The reduction in binding of ®bronectin-
treated S. aureus compared with untreated S. aureus was as follows:
OVA-sensitized/saline-challenged skin of BALB/C mice was from
57.94 6 8.23 to 26.17 6 3.93 (p < 0.005), and OVA-sensitized/
challenged skin of BALB/C mice was from 103.67 6 12.50 to
56.39 6 10.90 (p < 0.01). The respective reductions in binding of
the ®brinogen-treated S. aureus compared to the untreated S. aureus
were as follows: OVA-sensitized/saline-challenged skin of BALB/
C mice was from 57.94 6 8.23 to 24.50 6 2.98 (p < 0.001), and
OVA-sensitized/challenged skin of BALB/C mice was from
103.67 6 12.50 to 53.78 6 11.59 (p < 0.01). In contrast,
collagen-treated S. aureus did not show signi®cant reduction in
binding to the stratum corneum under any experimental
conditions. S. aureus incubated with 1% HSA as a control, under
the same incubation conditions as ECM proteins, showed no
signi®cant difference in adherence of bacteria to the skin. Thus, the
reduction in binding of S. aureus to the stratum corneum following
preincubation with ®bronectin or ®brinogen appeared secondary to
the speci®c blocking of MSCRAMM receptors.
Adherence of S. aureus mutant strains to mouse skin To
con®rm these results, an independent approach to identify the key
MCRAMMS involved in the binding of S. aureus to Th2-induced
skin in¯ammation was used. Staphylococcus aureus mutants with
selective de®ciencies in speci®c MCRAMMS were examined for
their ability to bind in¯amed mouse skin sites. As shown in Fig 5,
binding of S. aureus strain DU5883, which is an FnbpA- and
FnbpB-negative mutant, to OVA-sensitized/challenged skin of
BALB/C mice was markedly reduced compared to its parent 8325±
4 strain (p < 0.0005). Similarly, binding to OVA-sensitized/
challenged skin of S. aureus strain DU5944, which is a ClfA- and
ClfB-negative mutant, was signi®cantly less than its parent
Newman strain (p < 0.05). In contrast, the difference in binding
of S. aureus strain PH100, which is a Cna-negative mutant, to the
OVA-sensitized/challenged skin of BALB/C mice was not
signi®cantly less than its parent Phillips strain. These data con®rm
that ®bronectin and ®brinogen contribute to S. aureus binding to
in¯amed skin induced by Th2 cytokines.
Effects of IL-4 versus IFN-g on S. aureus binding To obtain
independent evidence that S. aureus binding is preferentially
increased to IL-4-stimulated skin, BALB/C mice skin explants
were incubated with recombinant IL-4 or recombinant IFN-g for
72 h. As shown in Fig 6, a signi®cantly greater number of S. aureus
from AD bound to IL-4-treated skin than IFN-g-treated skin (p
< 0.05) or skin that had been incubated in medium alone (p
< 0.0001). In contrast, the S. aureus DU5883 Fnbp-negative mutant
strain did not show any increased binding to IL-4-treated skin.
Induction of ®bronectin expression by IL-4 The failure of
the DU5883 S. aureus strain to show increased binding to IL-4-
Figure 1. Staphylococcus aureus binding to Th1- versus Th2-
mediated skin in¯ammation. Quanti®cation of AD S. aureus
adherence to the epidermis of BALB/C mouse skin [OVA/alum (n = 5)
and OVA/CFA sensitized (n = 4), OVA challenged], using an S. aureus
strain derived from AD that expressed FnBP, Can, and Clf. Consistent
with previous reports (Beck et al, 1989; Ke et al, 1995), we found that
CFA/OVA sensitization resulted in IFN-g production (18 pg per ml) but
no IL-4 (not detectable) production, whereas alum/OVA sensitization
resulted in IL-4 but little IFN-g (22 pg per ml vs 7 pg per ml,
respectively) production. The means 6 SD in bacterial binding between
OVA and saline challenged controls are shown for both sensitization
protocols (OVA/alum for the Th2 model and OVA/CFA for the Th1
model).
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treated skin suggested that IL-4-induced ®bronectin synthesis was
required for enhanced S. aureus binding. We therefore directly
examined ®bronectin expression in IL-4 versus IFN-g versus
medium control treated skin from WT BALB/C mice. As shown
in Fig 7, IL-4-treated skin showed a signi®cant increase in
®bronectin staining in the epidermis (mainly the stratum
corneum) compared with skin treated with medium control
alone (mean MFI = 1310 6 126 and 687 6 49, respectively; p
= 0.02). Interestingly, IFN-g-treated skin actually showed a
signi®cant decrease in ®bronectin expression compared to
medium alone (mean MFI = 453 6 48 and 687 6 49,
respectively; p = 0.01).
DISCUSSION
S. aureus colonization and infection of the skin is thought to play an
important role in the pathogenesis of a variety of chronic skin
diseases including AD, psoriasis, and cutaneous T cell lymphoma
(Leung et al, 1993a,b; Tokura et al, 1995; Bunikowski et al, 2000;
Leung, 2000). This relationship has been most convincingly
demonstrated in AD where the number of S. aureus colonizing
the skin correlates with disease severity and success of antistaphylo-
coccal antibiotic therapy used in combination with topical
corticosteroids for treatment of poorly controlled AD (Leyden et
al, 1974; Lever et al, 1988). The mechanism by which S. aureus
triggers the exacerbation of AD is an area of active investigation and
includes a role for the release of toxins known to act as
superantigens that stimulate marked activation of T cells and
macrophages (Kotzin et al, 1993; Leung et al, 1993b; Bunikowski
et al, 1999; Nomura et al, 1999).
One aspect of this disease that has largely been overlooked,
however, is the mechanism by which this bacterium is able to
preferentially colonize the skin of atopic individuals. In this regard,
the numbers of S. aureus reached on AD skin are frequently over 10
3 106 per cm2, which is far greater than seen in other forms of skin
in¯ammation (Hauser et al, 1985). Although multiple factors are
likely to control this process, the initial step in colonization is
binding of S. aureus to the skin. It was therefore of interest to
determine whether the atopic state itself is contributory to the
adherence process.
IL-4 is known to play a key role in the pathogenesis of atopic
diseases and is highly expressed in unaffected skin as well as acute
AD skin lesions (Hamid et al, 1994). It is important for IgE isotype
switching, development of Th2 cells, and induction of adhesion
molecules on endothelial cells that recruit eosinophils (Oettgen and
Geha, 1999). Indeed, a recent study of OVA-sensitized skin from
BALB/C mice demonstrated that deletion of the IL-4 gene results
in a remarkable decrease in eosinophil in®ltration at cutaneous sites
of allergen challenge (Spergel et al, 1999).
Our study reports a novel action of IL-4, i.e., the induction of S.
aureus binding to the skin. The critical role of IL-4 in this process is
supported by two key observations. First, S. aureus binding to
OVA-sensitized/challenged skin of BALB/C mice is reduced to
baseline in IL-4 KO mice (Fig 3). Second, incubation of normal
mouse skin with IL-4 induces increased S. aureus skin binding
(Fig 6). Although IFN-g can also increase S. aureus skin binding, it
was signi®cantly less effective than IL-4. This may partially account
for the observation that AD is associated with signi®cantly higher
levels of S. aureus skin colonization than found in psoriasis, which is
primarily a Th1-mediated disease.
An important issue that needs to be addressed is the mechanism
by which IL-4 induces S. aureus binding to the skin. It is known
that S. aureus express an array of adhesins termed MSCRAMMs
that allow it to bind ECM components and also certain plasma
proteins that can exudate into sites of skin in¯ammation (Foster and
HoÈoÈk, 1998). By utilizing these adhesins, initial adherence to the
skin occurs and the colonization process can begin. Therefore this
study also sought to examine the role of these MSCRAMMs and
their ligands (ECM and plasma proteins) on S. aureus binding to
atopic skin.
Our ®ndings indicate that ®bronectin and ®brinogen, but not
collagen, are the key MSCRAMMs used in the binding of S. aureus
to Th2-induced skin in¯ammatory reactions. This is supported by
the following observations. First, isogenic mutants of S. aureus that
were selectively de®cient in ®bronectin- or ®brinogen-binding
Figure 2. Staphylococcus aureus binding to skin
sections. Visualization of AD S. aureus (arrow)
adherence to epidermis in OVA-sensitized, saline-
challenged skin of BALB/C mice (A), and OVA/
alum-sensitized, OVA-challenged skin of BALB/
C mice (B). A broken black line differentiates the
dermal/epidermal junction.
Figure 3. AD S. aureus binding is dependent on IL-4. Comparison
of AD S. aureus binding to stratum corneum in BALB/C mice versus IL-
4 KO mice versus IFN-g KO mice that were either OVA sensitized/
saline challenged or OVA sensitized/challenged using S. aureus derived
from AD. The means 6 SEM in bacterial binding are shown for four
separate experiments.
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proteins demonstrated reduced binding to OVA-sensitized/chal-
lenged skin reactions (Fig 5). In contrast, a collagen adhesin-
negative mutant did not show decreased binding to Th2-mediated
in¯amed skin. Second, when S. aureus were preincubated with
either saline, HSA, ®bronectin, collagen, or ®brinogen in an
attempt to block the MSCRAMM receptors and thus interfere
with bacterial adherence, only ®bronectin and ®brinogen, but not
saline, collagen, or HSA, signi®cantly reduced the level of S. aureus
binding to Th2-induced skin in¯ammation sites (Fig 4). Of note,
the bacterial binding sites were mainly con®ned to the stratum
corneum.
Although ®bronectin and ®brinogen are plasma proteins that can
exudate from the blood at sites of skin in¯ammation, it is unlikely
that this represents the exclusive process by which S. aureus binding
is increased to atopic skin. In vitro incubation of skin explants from
normal mouse skin with recombinant IL-4 increased S. aureus
binding to a level signi®cantly greater than incubation of skin from
the same skin sites with either medium control or IFN-g.
Figure 6. Treatment of skin with IL-4 leads to enhanced S. aureus
binding. Quanti®cation of DU 5883 (Fnbp-negative) mutant strain and
its parent 8325±4 strain of S. aureus binding to the stratum corneum of
BALB/C mouse skin incubated with recombinant IL-4 (1000 U per ml)
or recombinant IFN-g (1000 U per ml) or medium alone at 37°C for
72 h. The means 6 SEM in bacterial binding are shown for four separate
experiments.
Figure 7. Visualization of ®bronectin staining in control medium
versus IFN-g versus IL-4 treated skin explants from BALB/C mice.
Marked differences can be seen in the epidermis of the three subject
groups, with IL-4-treated skin showing the greatest epidermal staining
for ®bronectin.
Figure 4. Staphylococcus aureus binding is blocked by ®bronectin
and ®brinogen. The effect of blocking MSCRAMM receptors by
preincubation of AD S. aureus with puri®ed ®bronectin, ®brinogen, and
collagen on the binding of S. aureus to the epidermis of BALB/C mice.
The means 6 SEM in bacterial binding are shown for four separate
experiments.
Figure 5. Quanti®cation of MSCRAMM mutant S. aureus strain
adherence to the stratum corneum of OVA-sensitized/challenged
BALB/C mice. Binding of each bacterial mutant strain was compared
to its corresponding WT parent strain. The means 6 SEM in bacterial
binding are shown for four separate experiments.
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Furthermore, IL-4 but not IFN-g also increased suprabasal
epidermal ®bronectin deposition. This suggests a selective
mechanism by which Th2, as compared to Th1, responses can
enhance S. aureus binding to the skin. This is consistent with
previous in vitro studies that have also demonstrated that IL-4, but
not IFN-g, can induce ®bronectin production by skin ®broblasts
(Clark, 1990; Postlethwaite et al, 1992). Thus, IL-4-induced
®bronectin synthesis, in combination with plasma exudation of
®brinogen, could provide a mechanism by which the atopic/
in¯ammatory environment mediates enhanced S. aureus attachment
to the skin. Interestingly, a recent study by Wann et al (2000)
demonstrated that the S. aureus ®bronectin-binding MSCRAMM
FnbpA is a bifunctional protein that also binds to ®brinogen. This
observation is consistent with our observations suggesting that
blocking the binding of S. aureus to ®brinogen and ®bronectin may
be an important therapeutic target for reduction of S. aureus
colonization in atopic skin.
In summary, using S. aureus mutant strains, de®cient in the
expression of selective MSCRAMMs, and mouse strains with
targeted deletions of cytokine genes, it has been possible to
demonstrate for the ®rst time a direct link between Th2-mediated
cutaneous in¯ammation and increased colonization of the skin by
S. aureus. Although ®bronectin and ®brinogen provide abundant
adherent sites for bacterial adherence, other adhesins may also be
involved as both ECM bacterial incubation and utilization of
MSCRAMM mutants of S. aureus did not totally abrogate the
binding of S. aureus. Nevertheless, our study provides an approach
for further investigation into the interactions between
MSCRAMMs and ECM components that initiate colonization of
host tissues. Additional studies are needed to identify other bio-
physiologic factors that support and perpetuate this colonization
process, as well as further growth of bacteria, once they attach to
in¯amed skin.
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